8-Isoprostane increases scavenger receptor A and matrix metalloproteinase activity in THP-1 macrophages, resulting in long-lived foam cells

European Journal of Clinical Investigation

Volumn 34, Issue 7, 2004, Pages 451-458

  Scholz, H ^a,c   Aukrust, P ^a,c   Damas J K ^a,c   Tonstad, S ^b   Sagen, E L ^a,c   Kolset, S O ^a,c   Hall, C ^a,c   Yndestad, A ^a,c   Halvorsen, B ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Apoptosis; Atherosclerosis; Free radicals; Macrophages; Matrix metalloproteinases

Indexed keywords

8 ISOPROSTANE; CASPASE; GELATINASE B; ISOPROSTANE DERIVATIVE; MESSENGER RNA; MOLECULAR MARKER; OIL; OXIDIZED LOW DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR; SCAVENGER RECEPTOR A; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL DEGENERATION; CELL FUNCTION; CELL PROTECTION; COLORIMETRY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REPRESSION; EVALUATION; EXAMINATION; FOAM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; LIPID STORAGE; MACROPHAGE; MASS; MITOCHONDRION; MODULATION; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CASPASES; DINOPROST; FOAM CELLS; HUMANS; MATRIX METALLOPROTEINASE 9; OXIDATIVE STRESS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, SCAVENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VASOCONSTRICTOR AGENTS;

EID: 3943112896     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2004.01376.x     Document Type: Article

References (39)

1. Rosenfeld ME. Inflammation, lipids, and free radicals: lessons learned from the atherogenic process. Semin Reprod Endocrinol 1998;16:249-61.
2. Morrow JD, Awad JA, Boss HJ, Blair IA, Roberts LJ. 2nd Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci USA 1992;89:10721-5.
3. Waddington EI, Puddey IB, Mori TA, Croft KD. Similarity in the distribution of F(2)-isoprostanes in the lipid subfractions of atherosclerotic plaque and in vitro oxidised low density lipoprotein. Redox Rep 2002;7:179-84.
4. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 1997;17:2309-15.
5. Voutilainen S, Morrow JD, Roberts LJ II, Alfthan G, Alho H, Nyyssönen K, Salonen JT. Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels. Arterioscler Thromb Vasc Biol 1999;19:1263-6.
6. Mezzetti A, Cipollone F, Cuccurullo F. Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm. Cardiovasc Res 2000;47:475-88.
7. Gniwotta C, Morrow JD, Roberts LJ, Kuhn H 2nd. Prostaglandin F2-like compounds, F2-isoprostanes, are present in increased amounts in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1997;17:3236-41.
8. Aukrust P, Berge RK, Ueland T, Aaser E, Damas JK, Wikeby L et al. Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. J Am Coll Cardiol 2001;37:485-91.
9. Libby P, Geng YJ, Aikawa M, Schoenbeck U, Mach F, Clinton SK et al. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol 1996;7:330-5.
10. Lafont A. Basic aspects of plaque vulnerability. Heart 2003;89:1262-7.
11. Lusis AJ. Atherosclerosis. Nature 2000;407:233-41.
12. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74.
13. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis. the good, the bad, and the ugly. Circ Res 2002;90:251-62.
14. Scholz H, Yndestad A, Damas JK, Waehre T, Tonstad S, Aukrust P, et al. 8-isoprostane increases expression of interleukin-8 in human macrophages through activation of mitogen-activated protein kinases. Cardiovasc Res 2003;59:945-54.
15. Halvorsen B, Aas UK, Kulseth MA, Drevon CA, Christiansen EN, Kolset SO. Proteoglycans in macrophages. characterization and possible role in the cellular uptake of lipoproteins. Biochem J 1998;331:743-52.
16. Basu SK, Goldstein JL, Anderson GW, Brown MS. Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts. Proc Natl Acad Sci USA 1976;73:3178-82.
17. Whitman SC, Sawyez CG, Miller DB, Wolfe BM, Huff MW. Oxidized type IV hypertriglyceridemic VLDL-remnants cause greater macrophage cholesteryl ester accumulation than oxidized LDL. J Lipid Res 1998;39:1008-20.
18. Stylianou E, Aukrust P, Kvale D, Muller F, Froland SS. IL-10 in HIV infection: increasing serum IL-10 levels with disease progression - down-regulatory effect of potent anti-retroviral therapy. Clin Exp Immunol 1999;116:115-20.
19. Gerlier D, Thomasset N. Use of MTT colorimetric assay to measure cell activation. J Immunol Meth 1986;94:57-63.
20. Yndestad A, Holm AM, Muller F, Simonsen S, Froland SS, Gullestad L et al. Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc Res 2003;60:141-6.
21. Cracowski JL, Durand T, Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol Sci 2002;23:360-6.
22. Pratico D, Iuliano L, Mauriello A, Spagnoli L, Lawson JA, Rokach J et al. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest 1997;100:2028-34.
23. Greaves DR, Gough PJ, Gordon S. Recent progress in defining the role of scavenger receptors in lipid transport, atherosclerosis and host defence. Curr Opin Lipidol 1998;9:425-32.
24. Linton MF, Fazio S. Class A scavenger receptors, macrophages, and atherosclerosis. Curr Opin Lipidol 2001;12:489-95.
25. Boullier A, Bird DA, Chang MK, Dennis EA, Friedman P, Gillotre-Taylor K et al. Scavenger receptors, oxidized LDL, and atherosclerosis. Ann NY Acad Sci 2001;947:214-22; discussion: 222-3.
26. Ishibashi S, Inaba T, Shimano H, Harada K, Inoue I, Mokuno H et al. Monocyte colony-stimulating factor enhances uptake and degradation of acetylated low density lipoproteins and cholesterol esterification in human monocyte-derived macrophages. J Biol Chem 1990;265:14109-17.
27. Hsu HY, Twu YC. Tumor necrosis factor-alpha-mediated protein kinases in regulation of scavenger receptor and foam cell formation on macrophage. J Biol Chem 2000;275:41035-48.
28. Bottalico LA, Wager RE, Agellon LB, Assoian RK, Tabas I. Transforming growth factor-beta 1 inhibits scavenger receptor activity in THP-1 human macrophages. J Biol Chem 1991;266:22866-71.
29. Newmeyer DD, Ferguson-Miller S. Mitochondria: releasing power for life and unleashing the machineries of death. Cell 2003;112:481-90.
30. Brault S, Martinez-Bermudez AK, Marrache AM, Gobeil F Jr, Hou X, Beauchamp M et al. Selective neuromicrovascular endothelial cell death by 8-Iso-prostaglandin F2alpha: possible role in ischemic brain injury. Stroke 2003;34:776-82.
31. Gaur U, Aggarwal BB. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 2003;66:1403-8.
32. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003;3:745-56.
33. Halvorsen B, Staff AC, Henriksen T, Sawamura T, Ranheim T. 8-iso-prostaglandin F (2alpha) increases expression of LOX-1 in JAR cells. Hypertension 2001;37:1184-90.
34. Wintergerst ES, Jelk J, Rahner C, Asmis R. Apoptosis induced by oxidized low density lipoprotein in human monocyte-derived macrophages involves CD36 and activation of caspase-3. Eur J Biochem 2000;267:6050-9.
35. Liao HS, Kodama T, Geng YJ. Expression of class A scavenger receptor inhibits apoptosis of macrophages triggered by oxidized low density lipoprotein and oxysterol. Arterioscler Thromb Vasc Biol 2000;20:1968-75.
36. Littlewood TD, Bennett MR. Apoptotic cell death in atherosclerosis. Curr Opin Lipidol 2003;14:469-75.
37. Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003;59:812-23.
38. Fam SS, Morrow JD. The isoprostanes: unique products of arachidonic acid oxidation - a review. Curr Med Chem 2003;10:1723-40.
39. Lim PS, Chang YM, Thien LM, Wang NP, Yang CC, Chen TT et al. 8-iso-prostaglandin F2alpha as a useful clinical biomarker of oxidative stress in ESRD patients. Blood Purif 2002;20:537-42.